BIODEXA PHARMACEUTICALS-ADR (BDRX) Forecast, Price Target & Analyst Ratings

NASDAQ:BDRX • US59564R8806

Current stock price

3.03 USD
-0.11 (-3.5%)
At close:
3.05 USD
+0.02 (+0.66%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIODEXA PHARMACEUTICALS-ADR (BDRX).

Forecast Snapshot

Consensus Price Target

Price Target
$35.70
+ 1,078.22% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
85.71%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$35.70
Upside
+ 1,078.22%
From current price of $3.03 to mean target of $35.70, Based on 7 analyst forecasts
Low
$35.35
Median
$35.70
High
$36.75

Price Target Revisions

1 Month
-80.56%
3 Months
-80.56%

Price Target Summary

7 Wall Street analysts provided a forecast for the next 12 months for BDRX. The average price target is 35.7 USD. This implies a price increase of 1078.22% is expected in the next year compared to the current price of 3.03.
The average price target has been revised downward by 80.56% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

BDRX Current Analyst RatingBDRX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0.5 1 1.5 2 2.5

Analyst Ratings History

BDRX Historical Analyst RatingsBDRX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6

Analyst Ratings Consensus

ChartMill Buy Consensus
85.71%
BDRX was analyzed by 7 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about BDRX.
In the previous month the buy percentage consensus was at a similar level.
BDRX was analyzed by 7 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2024-02-08Ladenburg ThalmannInitiate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2027

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2021 2022 2023 2024 2025 2026 2027
Revenue
YoY % growth
BDRX revenue by date.BDRX revenue by date.
578K
68.51%		699K
20.93%		381K
-45.49%
-100.00%		3.067K
EBITDA
YoY % growth
BDRX ebitda by date.BDRX ebitda by date.
-6.595M
30.24%		-8.589M
-30.24%		-7.731M
9.99%		N/A
-15.70%		N/A
5.47%		N/AN/A
EBIT
YoY % growth
BDRX ebit by date.BDRX ebit by date.
-6.998M
34.42%		-8.932M
-27.64%		-8.014M
10.28%		-11.249M
-14.79%		-13.779M
6.02%		-20.335M
-135.22%		-20.893M
-2.74%
Operating Margin
BDRX operating margin by date.BDRX operating margin by date.
-1,210.73%-1,277.83%-2,103.41%N/AN/AN/A-681,199.99%
EPS
YoY % growth
BDRX eps by date.BDRX eps by date.
N/AN/AN/A-3.92
99.61%		-2.61
33.34%		-2.94
-12.51%		-2.30
21.72%

All data in GBP

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in GBP

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

BDRX Yearly Revenue VS EstimatesBDRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2027 2M 4M 6M 8M
BDRX Yearly EPS VS EstimatesBDRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2023 2024 2025 2026 2027 -200 -400 -600 -800

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
N/A
EPS Next 5 Year
N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

BIODEXA PHARMACEUTICALS-ADR / BDRX Forecast FAQ

Can you provide the average price target for BIODEXA PHARMACEUTICALS-ADR stock?

7 analysts have analysed BDRX and the average price target is 35.7 USD. This implies a price increase of 1078.22% is expected in the next year compared to the current price of 3.03.

How many analysts cover BIODEXA PHARMACEUTICALS-ADR (BDRX) stock?

The number of analysts covering BIODEXA PHARMACEUTICALS-ADR (BDRX) is 7.